MATHEMATICAL MODEL OF IMMUNOTHERAPY RESPONSE TO ANTIBODIES AS A TREATMENT FOR CANCER

被引:0
|
作者
Simbawa, Eman [1 ]
Alharbi, Sara [1 ]
Aljohani, Jawaher [1 ]
Abosamra, Hala [1 ]
Aboushoushah, Samia [2 ]
Cristini, Vittorio [3 ]
机构
[1] King Abdulaziz Univ, Dept Math, Fac Sci, Jeddah 21589, Saudi Arabia
[2] King Abdulaziz Univ, Phys Dept, Fac Sci, Jeddah 21589, Saudi Arabia
[3] Houston Methodist Res Inst, Math Med Program, Houston, TX 77030 USA
关键词
antibodies; cancer; drug delivery; immunotherapy; mathematical modeling; MONOCLONAL-ANTIBODIES; THERAPY;
D O I
10.28919/cmbn/4570
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Immunotherapy is a significant cancer treatment as it uses the body's natural immune system to fight cancer. To help boost the immune system, monoclonal antibodies (MABs) are used as they bind to cancer cells helping the immune system recognize these cells. In this paper, we present a mathematical model of nonlinear partial differential equations describing the interaction between the immune cells, MABs, and cancer cells. After nondimensionalizing the model, we analyzed the long-term behavior and found later that it is consistent with the numerical results. Then, we calculated the numerical solutions of the model with different values of the parameters (relative growth rate of cancer cells and the number of immune cells that are removed after killing a cancer cell) to determine the values that help increase the effectiveness of the treatment. We have considered the continuous delivery of antibodies over a certain period of time. These simulations showed that immune cells will eradicate cancer if the number of immune cells that are removed after killing a cancer cell is less than one. However, if each immune cell kills only one cancer cell, then the treatment reduces the cancer to a steady state or almost a steady state. On the other hand, if the relative growth rate of cancer cells is very small and each cancer cell needs more than one immune cell to kill it, then again, we get a steady state for cancer. However, if the relative growth rate is not small, then the cancer will grow after an initial decrease. This study could be implemented into a clinical trial with different delivery protocols of the drug to improve cancer treatment.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [41] Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
    Guo, Xiaohan
    Wu, Yi
    Xue, Ying
    Xie, Na
    Shen, Guobo
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] Global existence for a mathematical model of the immune response to cancer
    Wei, Xuemei
    Guo, Cuihua
    NONLINEAR ANALYSIS-REAL WORLD APPLICATIONS, 2010, 11 (05) : 3903 - 3911
  • [43] A mathematical model with piecewise constant arguments of colorectal cancer with chemo-immunotherapy
    Bozkurt, Fatma
    Yousef, Ali
    Bilgil, Halis
    Baleanu, Dumitru
    CHAOS SOLITONS & FRACTALS, 2023, 168
  • [44] Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
    Blanco, Belen
    Dominguez-Alonso, Carmen
    Alvarez-Vallina, Luis
    CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5457 - 5464
  • [45] Checkpoint blocking antibodies in cancer immunotherapy
    Kyi, Chrisann
    Postow, Michael A.
    FEBS LETTERS, 2014, 588 (02) : 368 - 376
  • [46] VACCINES AND ANTIBODIES FOR CANCER IMMUNOTHERAPY A REVIEW
    Tekewe, Alemu
    PHARMACOPHORE, 2012, 3 (01): : 1 - 17
  • [47] Immunomodulatory antibodies for immunotherapy of ovarian cancer
    Dai, Min
    Hellstrom, Ingegerd
    Yip, Yuen Yee
    Wei, Huafeng
    Hellstrom, Karl Erik
    CLINICAL CANCER RESEARCH, 2015, 21
  • [48] Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response
    Smith, Melanie H.
    Bass, Anne R.
    ARTHRITIS CARE & RESEARCH, 2019, 71 (03) : 362 - 366
  • [49] Bispecific antibodies and diabodies for cancer immunotherapy
    Elsaesser-Beile, Ursula
    Buehler, Patrick
    IMMUNOTHERAPY, 2012, 4 (05) : 459 - 460
  • [50] Arthritis after Cancer Immunotherapy: Symptom Duration and Treatment Response
    Smith, Melanie H.
    Bass, Anne R.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69